The growing crisis of gram negatives

• Gram-negative resistance is increasing¹
• Current treatment options are limited^2,3
• The number of new antibacterial drug approvals remains low^4,5

New systemic antibacterials continue to decline^4,5

Carbapenem usage continues to rise dramatically⁶

Source: National Sales Perspective (NSP) Audit. IMS. January 2010.

Please see Select Usage Information below.

“While the search for new antibiotic options continues, there is urgent need to employ strategies that will slow the development of resistance to the current armamentarium, such as…encouraging early and aggressive empirical therapy…”
—Siegel, 2008⁹

Despite ongoing efforts, since 2005 only 1 systemic antibacterial with gram-negative coverage—doripenem—has been approved.⁵

When selecting an appropriate antimicrobial in this challenging environment...Choose the more active agent in the class first

A treatment strategy that supports select goals of antimicrobial stewardship

“Prevention of the development of resistant organisms by using the appropriate antibiotic at the appropriate dosage not only protects the patients in the institution, but it prolongs the useful life of the class of agents…”
—Amyes et al, 2007⁸

Please see Select Usage Information below.

References